0.00Open0.00Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover0.00%IV315.51%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kazia Therapeutics Stock Discussion
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients With Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR)
Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracrani...
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
SYDNEY, Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15thBiennial Ovarian Cancer Research Symposium, co-presented by American ...
+200% run within couple weeks. 😉
Placed as a placeholder.
Let's see......
hmmmmmm
still going down
No comment yet